60 Degrees Pharmaceuticals, Inc. (SXTP)
| Market Cap | 3.11M -30.1% |
| Revenue (ttm) | 1.31M +63.9% |
| Net Income | -8.09M |
| EPS | -7.92 |
| Shares Out | 2.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 162,800 |
| Open | 1.200 |
| Previous Close | 1.250 |
| Day's Range | 1.110 - 1.242 |
| 52-Week Range | 1.050 - 8.620 |
| Beta | 2.47 |
| Analysts | Buy |
| Price Target | 3.70 (+216.24%) |
| Earnings Date | Aug 14, 2026 |
About SXTP
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zi... [Read more]
Financial Performance
In 2025, SXTP's revenue was $1.41 million, an increase of 106.81% compared to the previous year's $681,345. Losses were -$7.87 million, -6.69% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SXTP stock is "Buy." The 12-month stock price target is $3.7, which is an increase of 216.24% from the latest price.
News
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medi...
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE ...
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
60 Degrees Pharma (Nasdaq: SXTP) secures exclusive option to develop castanospermine for tick-borne diseases, expanding its infectious disease pipeline.
60 Degrees Pharmaceuticals Proxy statement: Proxy filing
60 Degrees Pharmaceuticals filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicin...
60 Degrees Pharmaceuticals Slides: Investor presentation
60 Degrees Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter i...
60 Degrees Pharmaceuticals Proxy statement: Proxy filing
60 Degrees Pharmaceuticals filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-...
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious dise...
60 Degrees Pharmaceuticals Quarterly report: Q1 2026
60 Degrees Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 15, 2026.
60 Degrees Pharmaceuticals Earnings release: Q1 2026
60 Degrees Pharmaceuticals released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
60 Degrees Pharmaceuticals Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
ARAKODA's commercial growth is driven by both malaria prevention and emerging use in chronic babesiosis, with ongoing clinical trials aiming to expand its indications. Key milestones in 2024-2027 include diagnostic validation, interim clinical results, and a potential NDA submission.
60 Degrees Pharmaceuticals Announces 2025 Annual Results
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Ph...
60 Degrees Pharmaceuticals Annual report: Q4 2025
60 Degrees Pharmaceuticals has published its Q4 2025 annual report on March 30, 2026.
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
All three patients in 60 Degrees Pharma's expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategy Partnershi...
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines ...
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation.
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
60 Degrees Pharma opens enrollment at Mount Sinai for its B-FREE trial testing tafenoquine in chronic babesiosis, addressing a major unmet medical need.
60 Degrees Pharmaceuticals Earnings release: Q3 2025
60 Degrees Pharmaceuticals released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
60 Degrees Pharmaceuticals Quarterly report: Q3 2025
60 Degrees Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 13, 2025.
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
60 Degrees Pharma reports 223% YoY revenue growth in Q3 2025; advances babesiosis programs with Tulane, Mount Sinai, and MUMS canine designation plans.